Antisense oligonucleotides are short strands of synthetic nucleic acid used to inhibit gene expression through binding to targeted RNA molecules. They are used for the treatment of diseases like Duchenne muscular dystrophy, Huntington's disease, and Alzheimer's disease. Antisense oligonucleotides can specifically suppress targeted genes that cause infections and chronic conditions. The global antisense oligonucleotides market is estimated to be valued at US$ 2913.5 Mn in 2023 and is expected to exhibit a CAGR of 7.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The increasing adoption of antisense oligonucleotides for the treatment of neuromuscular diseases has accelerated the growth of this market. For example, nusinersen sold under the brand name Spinraza is approved for the treatment of spinal muscular atrophy. It helps in improving motor functions and delaying disease progression in patients. Similarly, therapies using antisense oligonucleotides are also being explored for treating Duchenne muscular dystrophy and myotonic dystrophy. The success of these therapies in clinical trials will further drive the demand for antisense oligonucleotides over the forecast period.
Segment Analysis
The global antisense oligonucleotides market is dominated by therapeutic applications sub segment. Antisense oligonucleotides have immense therapeutic potential to selectively inhibit target genes and are used in treating Huntington's diseases, cancer, cardiovascular diseases, and viral infections. Their high specificity to bind target mRNA makes them a preferred treatment option over small molecule drugs.
Key Takeaways
The Global Antisense Oligonucleotides Market Demand is expected to witness high growth.
Regional analysis: North America is expected to remain the dominant region during the forecast period owing to strong government support for research and development activities in the US. Additionally, growing adoption of advanced healthcare technologies also support the market growth.
Key players operating in the antisense oligonucleotides market are SICK AG, Hitachi Ltd., Honeywell International Inc., Hyundai Elevator Co. Ltd., Nidec MCE, Toshiba Elevators and Building Systems, Thames Valley Controls, and Mitsubishi Electric.
For more insights, Read- https://www.insightprobing.com/antisense-oligonucleotides-market-size-and-share/
Get more insights on this topic: https://shoutingstars.com/code-weavers-bioinformatics-unravelling-the-intricate-thread-of-biological-information-fabric
Comments
0 comment